Skip to main content Accessibility help
×
Home

Homocysteine, B-vitamins and CVD: Symposium on ‘Diet and CVD’

  • Helene McNulty (a1), Kristina Pentieva (a1), Leane Hoey (a1) and Mary Ward (a1)

Abstract

There is considerable interest in plasma homocysteine (tHcy) as a CVD risk factor. Although the secondary prevention trials published to date have been inconclusive in confirming a benefit of tHcy-lowering treatment with B-vitamins on CVD events generally, such studies are widely recognised to have been insufficiently powered to detect a significant effect for the predicted magnitude of association between tHcy and heart disease risk, and therefore cannot be interpreted as evidence that no relationship exists. In fact, a recent meta-analysis of clinical trials has confirmed that folic acid supplementation reduces the risk of stroke, particularly in individuals without a history of stroke. Evidence supporting a causal relationship between elevated tHcy and heart disease also comes from genetic studies. The most important genetic determinant of tHcy in the general population is the common C677T variant in methylenetetrahydrofolate reductase (MTHFR) that results in higher tHcy. Individuals with the homozygous mutant (TT) genotype have a significantly higher (14–21%) risk of heart disease. Plasma tHcy is very responsive to intervention with the B-vitamins required for its metabolism, in particular folic acid, and to a lesser extent vitamins B12 and B6. Thus, although primarily aimed at reducing neural-tube defects, folic acid fortification may have an important role in the primary prevention of CVD via tHcy lowering. Besides folate, riboflavin is required as a cofactor for MTHFR and enhanced riboflavin status results in a marked lowering in tHcy specifically in individuals with the TT genotype, presumably by neutralising the variant form of the enzyme. About 10% of the UK and Irish populations have the TT genotype. In the present paper the potential role of folate and related B-vitamins in the primary prevention of CVD and the implications for nutrition policy are explored.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Homocysteine, B-vitamins and CVD
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Homocysteine, B-vitamins and CVD
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Homocysteine, B-vitamins and CVD
      Available formats
      ×

Copyright

Corresponding author

*Corresponding author: Professor Helene McNulty, fax +44 28 7032 4965, email h.mcnulty@ulster.ac.uk

References

Hide All
1.Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke. JAMA 288, 20152022.
2.Wald, DS, Law, M & Morris, JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 325, 12021208.
3.Toole, JF, Malinow, MR, Chambless, LE, Spence, JD, Pettigrew, LC, Howard, VJ, Sides, EG, Wang, CH & Stampfer, M (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. JAMA 291, 565575.
4.The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354, 15671577.
5.Bonaa, KH, Njølstad, I, Ueland, PM et al. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354, 16291632.
6.B-Vitamin Treatment Trialists' Collaboration (2006) Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 151, 282287.
7.Wang, X, Qin, X, Demirtas, H, Li, J, Mao, G, Huo, Y, Sun, N, Liu, L & Xu, X (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369, 18761882.
8.Yang, Q, Botto, LD, Erickson, JD, Berry, RJ, Sambell, C, Johansen, H & Friedman, JM (2006) Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 113, 13351343.
9.Wilcken, B, Bamforth, F, Li, Z et al. (2003) Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet 40, 619625.
10.Frosst, P, Blom, HJ, Milos, R et al. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10, 111113.
11.Klerk, M, Verhoef, P, Clarke, R, Blom, HJ, Kok, FJ & Schouten, EG (2003) MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288, 20232031.
12.Lewis, SJ, Ebrahim, S & Davey Smith, G (2005) Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate. Br Med J 331, 10531056.
13.Homocysteine Lowering Trialists' Collaboration (1998) Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. Br Med J 316, 894898.
14.Ward, M, McNulty, H, McPartlin, J, Strain, JJ, Weir, DG & Scott, JM (1997) Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. QJM 90, 519524.
15.Daly, S, Mills, JL, Molloy, AM, Conley, M, McPartlin, J, Lee, YJ, Young, PB, Kirke, PN, Weir, DG & Scott, JM (2002) Low-dose folic acid lowers plasma homocysteine levels in women of child-bearing age. QJM 95, 733740.
16.Wald, DS, Bishop, L, Wald, NJ, Law, M, Hennessy, E, Weir, D, McPartlin, J & Scott, J (2001) Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med 161, 695700.
17.Homocysteine Lowering Trialists' Collaboration (2005) Dose-dependant effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 82, 806812.
18.Tighe, P, Ward, M, McNulty, H, Finnegan, O, Strain, JJ, Dunne, A, Molloy, AM & Scott, JM (2004) Plasma homocysteine response to folic acid intervention in ischaemic heart disease patients: implications for food fortification policy. Proc Nut Soc 63, 51A.
19.Troen, AM, Mitchell, B, Sorensen, B et al. (2006) Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr 136, 189194.
20.Cole, BF, Baron, JA, Sandler, RS et al. (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297, 23512359.
21.Seal, EC, Metz, J, Flicker, L & Melny, J (2002) A randomized, double-blind, placebo-controlled study of oral vitamin B12 supplementation in older patients with subnormal or borderline serum vitamin B12 concentrations. J Am Geriatr Soc 50, 146151.
22.Eussen, SJPM, De Groot, LCPGM, Clarke, R, Schneede, J, Ueland, PM, Hoefnagels, WHL & van Staveren, WA (2005) Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency. Arch Intern Med 165, 11671172.
23.Quinlivan, EP, McPartlin, J, McNulty, H, Ward, M, Strain, JJ, Weir, DG & Scott, JM (2002) Importance of both folic acid and vitamin B-12 in reduction of risk of vascular disease. Lancet 359, 227228.
24.Liaugaudas, G, Jacques, PF, Selhub, J, Rosenberg, IH & Boston, AG (2001) Renal insufficiency, vitamin B-12 status, and population attributable risk for mild hyperhomocysteinemia among coronary artery disease patients in the era of folic acid-fortified cereal grain flour. Arterioscler Thromb Vasc Biol 21, 849851.
25.Johnson, MA, Hawthorne, NA, Brackett, WR, Fischer, JG, Gunter, EW, Allen, RH & Stabler, SP (2003) Hyperhomocysteinemia and vitamin B-12 deficiency in elderly using Title IIIc nutrition services. Am J Clin Nutr 77, 211220.
26.Robertson, J, Lemolo, F, Stabler, SP, Allen, RH & Spence, JD (2005) Vitamin B12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products. Can Med Assoc J 172, 15691573.
27.Spence, JD, Bang, H, Chambless, LE & Stampfer, MJ (2005) Vitamin intervention for stroke prevention trial: an efficacy analysis. Stroke 36, 24042409.
28.Wolters, M, Strohle, A & Hahn, A (2004) Cobalamin: a critical vitamin in the elderly. Prev Med 39, 12561266.
29.McKinley, MC, McNulty, H, McPartlin, J, Strain, JJ, Pentieva, K, Ward, M, Weir, DG & Scott, JM (2001) Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine levels in healthy elderly persons who are folate and riboflavin replete. Am J Clin Nutr 73, 759764.
30.Tsuge, H, Hotta, N & Hayakawa, T (2000) Effect of vitamin B6 on (n-3) polyunsaturated fatty acid metabolism. J Nutr 130, Suppl., 333S334S.
31.Chang, SJ, Chang, CN & Chen, CW (2002) Occupancy of glycoprotein IIb/IIIa by B6 vitamers inhibit human platelet aggregation. J Nutr 132, 36033606.
32.Matsubara, K, Matsumoto, H, Mizuchina, Y, Lee, JS & Kato, N (2003) Inhibitory effect of pyridoxal 5′-phosphate on endothelial cell proliferation, replicative DNA polymerase and DNA topoisomerase. Int J Mol Med 12, 5155.
33.Rimm, EB, Willett, WC, Hu, FB, Sampson, L, Colditz, GA, Manson, JE, Hennekens, C & Stampfer, MJ (1998) Folate and vitamin B6 from diet and supplements in relation to risk in coronary heart disease among women. JAMA 279, 359364.
34.Chasan-Taber, L, Selhub, J, Rosenberg, IH, Malinow, MR, Terry, P, Tishler, PV, Willett, W, Hennekens, CH & Stampher, MJ (1996) A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 15, 136143.
35.Robinson, K, Arheart, K, Refsum, H et al. (1998) Low circulating folate and vitamin B6 concentrations: risk factors for stroke, periphery vascular disease, and coronary vascular disease. European COMAC group. Circulation 97, 437443.
36.Folsom, AR, Nieto, FJ, McGovern, PG, Tsai, MY, Malinow, MR, Eckfeldt, JH, Hess, DL & Davis, CE (1998) Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 98, 204210.
37.Kelly, PJ, Shih, VE, Kistler, JP, Barron, M, Lee, H, Mandell, R & Furie, KL (2003) Low vitamin B6 but not homocyst(e)ine is associated with increased risk of stroke and transient ischemic attack in the era of folic acid grain fortification. Stroke 34, e51e54.
38.Kelly, PJ, Kistler, JP, Shih, VE, Mandell, R, Atassi, N, Barron, M, Lee, H, Silveira, S & Furie, KL (2004) Inflammation, homocysteine and vitamin B6 status after ischemic stroke. Stroke 35, 1215.
39.Friso, S, Jacques, PF, Wilson, PWF, Rosenberg, IH & Selhub, J (2001) Low circulating vitamin B6 is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 103, 27882791.
40.Clarke, R, Lewington, S, Sherliker, P & Armitage, J (2007) Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia. Curr Opin Clin Nutr Metab Care 10, 3239.
41.Molloy, AM, Daly, S, Mills, JL, Kirke, PN, Whitehead, AS, Ramsbottom, D, Conley, MR, Weir, DG & Scott, JM (1997) Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 349, 15911593.
42.Jacques, PF, Bostom, AG, Williams, RR, Ellison, RC, Eckfeldt, JH, Rosenberg, IH, Selhub, J & Rozen, R (1996) Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93, 79.
43.Brattström, L, Wilcken, DEL, Ohrvik, J & Brudin, L (1998) Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease – the result of a meta-analysis. Circulation 98, 25202526.
44.Yamada, K, Chen, Z, Rozen, R & Matthews, RG (2001) Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci USA 98, 1485314858.
45.Jacques, PF, Kalmbach, R, Bagley, PJ, Russo, GT, Rogers, G, Wilson, PW, Rosenberg, IH & Selhub, J (2002) The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. J Nutr 132, 283288.
46.Hustad, S, Ueland, PM, Vollset, SE, Zhang, Y, Bjorke-Monsen, AL & Schneede, J (2000) Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 46, 10651071.
47.McNulty, H, McKinley, MC, Wilson, B, McPartlin, J, Strain, JJ, Weir, DG & Scott, JM (2002) Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements. Am J Clin Nutr 76, 436441.
48.McNulty, H, Dowey, LC, Strain, JJ, Dunne, A, Ward, M, Molloy, AM, McAnena, LB, Hughes, JP, Hannon-Fletcher, M & Scott, JM (2006) Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C→T polymorphism. Circulation 113, 7480.
49.McKinley, MC, McNulty, H, McPartlin, J, Strain, JJ & Scott, JM (2002) Effect of riboflavin supplementation on plasma homocysteine in elderly people with low riboflavin status. Eur J Clin Nutr 56, 850856.
50.Horigan, G, Ward, M, McNulty, H, Purvis, J, Strain, JJ & Scott, JM (2007). Riboflavin lowers blood pressure in patients with premature CVD homozygous for the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism. Proc Nut Soc 66, 95A.
51.Jacques, PF, Selhub, J, Bostom, AG, Wilson, PWF & Rosenberg, IH (1999) The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Eng J Med 340, 14491454.

Keywords

Homocysteine, B-vitamins and CVD: Symposium on ‘Diet and CVD’

  • Helene McNulty (a1), Kristina Pentieva (a1), Leane Hoey (a1) and Mary Ward (a1)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed